https://www.marketscreener.com/quote/stock/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Results-from-Phase-2-Study-of-Fazirsiran-in-Patients-with-Alpha-1-Antitrypsin-Deficiency-Pu-40845650/?utm_source=telegram&utm_medium=social&utm_campaign=share